#United States #San Diego #Financial Growth #QuidelOrtho #Diagnostics Leader

QuidelOrtho Reports Financial Performance for 2025

QuidelOrtho Corporation, a prominent name in in vitro diagnostics, recently unveiled its financial performance for the fourth quarter and overall results for the fiscal year ending December 28, 2025. According to Brian J. Blaser, the President and CEO, the company navigated through a transition phase, moving away from the uncertainties driven by COVID-19, emerging with a more diversified and resilient diagnostics business.

Key Highlights from 2025 Financial Results

In the fourth quarter alone, QuidelOrtho's total revenue reached $724 million, marking a significant contribution from its Labs segment, which experienced an 8% growth year-over-year. Notable segments within Labs and Immunohematology showcases a consistent growth trajectory. Additionally, respiratory revenues reported a decline of 14%, attributed to reduced COVID-19 testing demand. Flu revenue, however, depicted a positive trend with a 6% growth.

Total revenue for the entire year stood at $2.73 billion, of which non-respiratory revenue contributed significantly at $2.33 billion. Although respiratory revenue dropped by 20%, the overall figures reflect a steady underlying business, which delivered an adjusted EBITDA of $597 million, translating to a favorable 22% margin.

Insights on Future Growth

QuidelOrtho is optimistic about enhancing its cash flow, expecting improvements of more than $200 million in the upcoming fiscal year 2026. This projection is buoyed by the emphasis on cost-saving strategies implemented in 2025. With an unwavering commitment to innovation, QuidelOrtho aims to solidify its position in the diagnostics market.

CEO Blaser remarked on leveraging the company’s established framework to execute their 2026 growth priorities, alongside a strong leadership transition plan as the CFO, Joseph M. Busky, prepares for retirement in June 2026.

Financial Guidance for 2026

For the fiscal year 2026, QuidelOrtho has set ambitious goals, with total revenue expectations to range from $2.7 billion to $2.9 billion. Adjusted EBITDA is forecasted to rise to between $630 million and $670 million, with a targeted adjusted EBITDA margin of approximately 23.3%.

As the conference call summary revealed, QuidelOrtho remains committed to advancing diagnostics, ensuring access to timely and reliable results that can enhance patient outcomes. Key initiatives and improvements within the framework will further enable strategic operational excellence.

In conclusion, as QuidelOrtho moves on to a promising phase, the focus will remain on innovation, operational efficiencies, and strategic growth to navigate the evolving landscape of diagnostics.